Moreover, LINC01138 has been reported as a tumor promoter that can exert its biological functions via the tumor-related IGF2BP1/IGF2BP3-LINC01138-PRMT5 axis in hepatocellular carcinoma (HCC), which can serve as a robust biomarker and therapeutic target for HCC [30]. This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.